According to The Australian Financial Review, Sydney-based biotech EnGeneIC is tapping investors to raise $20 million in bridging funding to buy time until the IPO market reopens and the company can undertake a Nasdaq listing next year.
The company, which was founded in 2001 by former CSIRO scientists Jennifer MacDiarmid and Himanshu Brahmbhatt, who still serve as co-CEOs, has created a new way of delivering cancer drugs that is more potent and less toxic than existing treatments.
Subscribe to our English Newsletter
© Japan Australia Business Creators Pty Ltd | All Rights Reserved. Website designed and developed by Japan Australia Business Creators Pty Ltd.